Diabetes Drug Ozempic Shortage in Greece: Weight Loss Controversy Raises Alarm
Maria and Nikos use Ozempic, a drug for different health issues. Maria, 60, takes it for Type 3 diabetes. Nikos, 39, uses it for weight loss, although it is not approved for that purpose. Many people are now aware of Ozempic’s weight-loss effects, making it hard for diabetics like Maria to access the drug.
Maria finds it challenging to obtain her medication but relies on her pharmacist friend for help. She originally had a prescription for a specific dosage, but due to supply issues, she must now take a higher dose. She expresses gratitude for her pharmacist’s support.
The active ingredient in Ozempic is semaglutide. It controls blood sugar levels in diabetes patients. There is a higher dose of semaglutide available as Wegovy, which is approved for treating obesity. However, Wegovy is not available in Greece and is in low supply elsewhere.
How can patients advocate for better access to diabetes medications like Ozempic amidst shortages?
Interview with Dr. Elena Kostas, Endocrinologist Specializing in Diabetes Treatment
By: News Directory 3
ND3: Thank you for joining us today, Dr. Kostas. Given the increasing use of Ozempic, particularly for weight loss, how has this impacted access for diabetes patients like Maria?
Dr. Kostas: Thank you for having me. The rising interest in Ozempic for weight loss has created significant supply issues. Patients like Maria, who depend on it to manage their Type 3 diabetes, face challenges securing their prescribed dosages. The demand has surged, and unfortunately, supply hasn’t kept up, leading to frustrations for those needing it for its approved use.
ND3: Can you explain the FDA’s approval distinctions between Ozempic and its higher dose counterpart, Wegovy?
Dr. Kostas: Certainly. Ozempic, whose active ingredient is semaglutide, is approved for the management of Type 2 diabetes. Wegovy, on the other hand, is specifically approved for the treatment of obesity. Both contain the same active ingredient but are intended for different uses. In certain regions like Greece, Wegovy isn’t available, further constraining options for weight management.
ND3: The case of Maria having to take a higher dosage due to shortages is concerning. Can this affect her health in any way?
Dr. Kostas: Taking a higher dosage than prescribed can lead to potential side effects. It’s essential for patients to follow their doctor’s guidance regarding their medications. For Maria, the increased dosage might provide insufficient blood sugar control. Her situation highlights the critical need for consistent access to medications.
ND3: What advice would you give to patients experiencing difficulty in obtaining their prescribed Ozempic dosages?
Dr. Kostas: Firstly, I encourage them to communicate openly with their healthcare providers. Exploring alternative medications or strategies for managing glucose levels might be necessary. Pharmacists, like Maria’s friend, can play a vital role in finding solutions or potential alternatives. It’s crucial not to self-adjust doses without professional guidance.
ND3: Nikos’s journey also sheds light on how some patients are using Ozempic beyond its approved use. What are the risks associated with off-label use?
Dr. Kostas: Off-label use of medications can come with its own set of risks. While some patients, like Nikos, may experience weight loss, there can also be unintended consequences, including metabolic changes or other health complications. It’s vital for patients using Ozempic for non-approved reasons to do so under strict medical supervision.
ND3: With the current landscape, what is your outlook on Ozempic’s availability in the future?
Dr. Kostas: I remain cautiously optimistic. Pharmaceutical companies are often working to address supply chain issues, and hopefully, we will see more consistent availability in the market. However, we must advocate for patients needing these medications most, ensuring those with diabetes receive the essential treatments they require.
ND3: Thank you, Dr. Kostas, for your insights on this pressing issue.
Dr. Kostas: Thank you for bringing attention to this important topic. It’s vital that we continue to support both diabetes patients and those seeking weight management solutions in a safe and effective manner.
Nikos learned about Ozempic and visited a doctor for a check-up. The doctor recommended a 0.5 mg dose. After nine months of use, he has lost 13 kilograms.
Currently, there is a shortage of the 0.5 and 0.25 mg doses. This situation forces Maria to take 1 mg, which is twice her prescribed amount. As interest in Ozempic grows for weight loss, the availability for diabetes treatment continues to decline.